{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:49:50Z","timestamp":1783396190027,"version":"3.54.6"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Continuing prostate-specific antigen (PSA) screening after age 70 years might benefit men at high risk of prostate cancer\u2013specific mortality (PCSM) or metastatic prostate cancer (mPCa), but the relative value of clinical factors (race and ethnicity, competing mortality, and PSA history) in identifying men at higher vs lower risk is unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the value of PSA levels, race and ethnicity, and competing mortality in risk stratification for PCSM and mPCa in men after age 70 years.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this cohort study, clinical data of all men receiving health care through the Veterans Health Administration who turned age 70 years between 2008 and 2020 and had a normal screening PSA value between age 65 and 69 years (&amp;lt;4 ng\/mL [baseline PSA]) and no prior history of prostate cancer or biopsy were examined. The data cutoff date was December 26, 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>The most recent screening PSA value from age 65 to 69 years, self-reported race and ethnicity, and competing mortality risk derived from a machine learning model.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>The 10-year absolute risk of PCSM and mPCa were determined using regression modeling.<\/jats:p><\/jats:sec>Results<\/jats:title>The cohort included 921\u202f609 men who turned 70 years between 2008 and 2020; 11% of whom self-reported as Black and 82% as White race. Between age 65 and 70 years, 45% of patients had a baseline PSA of less than 1.00 ng\/mL, and 32% had a baseline PSA of 1.00 to 1.99 ng\/mL. Most patients (87%) continued to undergo screening past age 70 years, with little variation by competing mortality risk or race and ethnicity. The 10-year cumulative incidence of PCSM was 0.26% overall, and 95% of men had a 10-year risk less than 0.73%. Higher baseline PSA level between age 65 and 69 years was associated with 10-year PCSM risk (0.79% for 3.00-3.99 ng\/mL vs 0.10% for 0.20-0.99 ng\/mL), race and ethnicity (0.36% for Black vs 0.25% for White), and competing mortality (0.24% for the highest quintile vs 0.21% for the lowest quintile). Similar results were found for mPCa. Low PSA (0.20-0.99 ng\/mL) was associated with very low PCSM and mPCa risk, even among Black men in the healthiest quintile of competing mortality risk (10-year PCSM risk, 0.08% [95% CI, 0.01%-0.44%]; 10-year mPCa risk 0.24% [95% CI, 0.10%-0.52%]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, the findings suggest that most men receiving care through the VHA continue PSA screening after age 70 years despite low absolute 10-year PCSM risks. The PSA values from age 65 to 69 years may be highly informative for adverse prostate cancer outcomes after age 70 years, with a PSA less than 1 ng\/mL associated with a very low risk of long-term PCSM and mPCa.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.59766","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T16:31:44Z","timestamp":1739550704000},"page":"e2459766","source":"Crossref","is-referenced-by-count":6,"title":["Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening"],"prefix":"10.1001","volume":"8","author":[{"given":"Dana H.","family":"Chung","sequence":"first","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner J.","family":"Caverly","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Schipper","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Department of Biostatistics, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hofer","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Gulati","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent S.","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E. V.","family":"Caram","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe A.","family":"Tsao","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian D.","family":"Stensland","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"},{"name":"Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Elliott","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer D.","family":"Saini","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex K.","family":"Bryant","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"},{"name":"Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"5","key":"zoi241669r1","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bju.14580","article-title":"Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.","volume":"123","author":"Pinsky","year":"2019","journal-title":"BJU Int"},{"issue":"1","key":"zoi241669r2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer.","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"17","key":"zoi241669r3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial.","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"issue":"18","key":"zoi241669r4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement.","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"zoi241669r5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening.","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"key":"zoi241669r7","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300289","article-title":"Prostate Cancer Foundation screening guidelines for Black men in the United States.","author":"Garraway","year":"2024","journal-title":"NEJM Evid"},{"issue":"4","key":"zoi241669r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.7504","article-title":"Low-value prostate-specific antigen screening in older males.","volume":"6","author":"Kalavacherla","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi241669r9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1741-7015-12-26","article-title":"Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.","volume":"12","author":"Vickers","year":"2014","journal-title":"BMC Med"},{"issue":"5","key":"zoi241669r10","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/JU.0000000000000346","article-title":"Personalized risks of over diagnosis for screen detected prostate cancer incorporating patient comorbidities: estimation and communication.","volume":"202","author":"Gulati","year":"2019","journal-title":"J Urol"},{"issue":"3","key":"zoi241669r11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/01.ju.0000169255.64518.fb","article-title":"Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.","volume":"174","author":"Etzioni","year":"2005","journal-title":"J Urol"},{"issue":"12","key":"zoi241669r12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jamaoncol.2022.4319","article-title":"Association of prostate-specific antigen screening rates with subsequent metastatic prostate cancer incidence at US Veterans Health Administration facilities.","volume":"8","author":"Bryant","year":"2022","journal-title":"JAMA Oncol"},{"key":"zoi241669r13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/CCI.21.00030","article-title":"Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing.","volume":"5","author":"Alba","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"zoi241669r14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"7","key":"zoi241669r15","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index.","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"zoi241669r16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/aje\/kwu289","article-title":"Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count.","volume":"181","author":"Dong","year":"2015","journal-title":"Am J Epidemiol"},{"issue":"29","key":"zoi241669r17","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1002\/sim.5459","article-title":"Absolute risk regression for competing risks: interpretation, link functions, and prediction.","volume":"31","author":"Gerds","year":"2012","journal-title":"Stat Med"},{"issue":"70","key":"zoi241669r18","first-page":"2079","article-title":"On over-fitting in model selection and subsequent selection bias in performance evaluation.","volume":"11","author":"Cawley","year":"2010","journal-title":"J Mach Learn Res"},{"issue":"23","key":"zoi241669r19","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","article-title":"Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer.","volume":"34","author":"Preston","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi241669r20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.eururo.2018.02.016","article-title":"Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men.","volume":"73","author":"Sjoberg","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"zoi241669r21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2023.10.011","article-title":"Prostate cancer mortality among elderly men after discontinuing organised screening: long-term results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.","volume":"85","author":"de Vos","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"zoi241669r22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2018.08.032","article-title":"Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in Black men.","volume":"75","author":"Preston","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"zoi241669r23","first-page":"13","article-title":"Current and projected characteristics and unique health care needs of the patient population served by the Department of Veterans Affairs.","volume":"5","author":"Eibner","year":"2016","journal-title":"Rand Health Q"},{"issue":"9","key":"zoi241669r24","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/cncr.23695","article-title":"Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.","volume":"113","author":"Chamie","year":"2008","journal-title":"Cancer"},{"key":"zoi241669r6","unstructured":"NCCN guidelines: prostate cancer early detection (version 2.2024). National Comprehensive Cancer Network. Accessed June 6, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1460"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2830234\/chung_2025_oi_241669_1742564222.95165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T15:06:03Z","timestamp":1743087963000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2830234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.59766","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}